<!doctype html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta name="viewport" content="width=device-width,initial-scale=1"/>
<title>Understanding Non-Approved Breast Cancer Screening Methods</title>
<style>
  :root{
    --bg:#0b1020;
    --panel:#0f1730;
    --panel2:#121c3a;
    --text:#eaf0ff;
    --muted:#b7c2e6;
    --accent:#7aa2ff;
    --accent2:#45d483;
    --border:rgba(255,255,255,.12);
    --shadow:0 10px 30px rgba(0,0,0,.35);
    --radius:16px;
    --mono: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace;
    --sans: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, "Helvetica Neue", Arial, "Noto Sans", "Liberation Sans", sans-serif;
  }
  *{box-sizing:border-box}
  body{
    margin:0;
    font-family:var(--sans);
    background:radial-gradient(1200px 800px at 20% 10%, rgba(122,162,255,.25), transparent 60%),
               radial-gradient(900px 700px at 80% 30%, rgba(69,212,131,.15), transparent 60%),
               var(--bg);
    color:var(--text);
    line-height:1.55;
  }
  a{color:var(--accent); text-decoration:none}
  a:hover{text-decoration:underline}
  header{
    position:sticky; top:0; z-index:50;
    background:rgba(11,16,32,.82);
    backdrop-filter: blur(10px);
    border-bottom:1px solid var(--border);
  }
  .wrap{max-width:1100px; margin:0 auto; padding:16px 18px}
  .topbar{display:flex; gap:14px; align-items:center; justify-content:space-between;}
  .brand{display:flex; gap:12px; align-items:center}
  .logo{
    width:44px; height:44px; border-radius:14px;
    background:linear-gradient(135deg, rgba(122,162,255,.9), rgba(69,212,131,.8));
    box-shadow:var(--shadow);
  }
  .title h1{margin:0; font-size:16px; letter-spacing:.2px}
  .title p{margin:2px 0 0; color:var(--muted); font-size:12px}

  .siteNav{display:flex; gap:8px; align-items:center; flex-wrap:wrap; margin-left:auto}
  .siteNav a{
    display:inline-flex; align-items:center; gap:6px;
    padding:8px 10px;
    border-radius:999px;
    border:1px solid var(--border);
    background:rgba(15,23,48,.6);
    color:var(--muted);
    font-size:12px;
    text-decoration:none;
    white-space:nowrap
  }
  .siteNav a:hover{
    background:rgba(122,162,255,.12);
    border-color:rgba(122,162,255,.25);
    color:var(--text);
    text-decoration:none
  }
  .siteNav a.active{
    background:rgba(69,212,131,.14);
    border-color:rgba(69,212,131,.35);
    color:var(--text)
  }
  .siteNav .dot{
    width:6px; height:6px; border-radius:99px; display:inline-block;
    background:rgba(69,212,131,.9);
    box-shadow:0 0 0 3px rgba(69,212,131,.12)
  }

  .card{
    border:1px solid var(--border);
    border-radius:var(--radius);
    background:rgba(15,23,48,.58);
    box-shadow:var(--shadow);
    overflow:hidden;
  }
  .card + .card{margin-top:16px}
  .card .hdr{
    padding:16px;
    border-bottom:1px solid var(--border);
    background:rgba(18,28,58,.55);
    display:flex; align-items:flex-start; justify-content:space-between; gap:12px;
  }
  .card .hdr h2{margin:0; font-size:15px}
  .card .hdr p{margin:6px 0 0; color:var(--muted); font-size:12px}
  .card .body{padding:16px; font-size:14px; color:var(--text)}
  .note{
    border-left:4px solid rgba(122,162,255,.65);
    padding:10px 12px;
    border-radius:12px;
    background:rgba(122,162,255,.10);
    color:var(--text);
    font-size:13px;
  }

  details{
    border:1px solid var(--border);
    border-radius:14px;
    background:rgba(15,23,48,.45);
    overflow:hidden;
  }
  summary{
    cursor:pointer;
    padding:12px 14px;
    list-style:none;
    display:flex; align-items:center; justify-content:space-between; gap:10px;
    background:rgba(18,28,58,.4);
  }
  summary::-webkit-details-marker{display:none}
  summary .sleft{display:flex; flex-direction:column; gap:2px}
  summary .sleft b{font-size:13px}
  summary .sleft span{font-size:12px; color:var(--muted)}
  .detailbody{padding:12px 14px; font-size:13px; color:var(--text)}

  .refs{display:grid; gap:10px;}
  .ref{
    border:1px solid var(--border);
    border-radius:14px;
    background:rgba(15,23,48,.45);
    padding:12px 14px;
  }
  .ref .rid{font-family:var(--mono); font-size:12px; color:var(--muted)}
  .ref .rbody{font-size:13px; margin-top:6px}

  sup.cite{font-size:11px; margin-left:2px;}
  sup.cite a{
    color:var(--accent);
    padding:2px 4px;
    border-radius:8px;
    border:1px solid rgba(122,162,255,.35);
    background:rgba(122,162,255,.12);
    text-decoration:none;
  }
  sup.cite a:hover{background:rgba(122,162,255,.18)}

  .grid{display:grid; grid-template-columns:repeat(auto-fit, minmax(260px,1fr)); gap:16px}
  .tile{
    border:1px solid var(--border);
    border-radius:var(--radius);
    background:rgba(15,23,48,.55);
    box-shadow:var(--shadow);
    padding:16px;
  }
  .tile h3{margin:0 0 8px}
  .tile p{margin:0; color:var(--muted); font-size:13px}
  .badge{
    display:inline-block;
    margin-top:12px;
    padding:6px 10px;
    border-radius:999px;
    border:1px solid var(--border);
    background:rgba(69,212,131,.12);
    color:var(--text);
    font-size:12px;
  }
</style>
</head>
<body>
<header>
  <div class="wrap topbar">
    <div class="brand">
      <div class="logo" aria-hidden="true"></div>
      <div class="title">
        <h1>Understanding Non-Approved Breast Cancer Screening Methods</h1>
        <p>Common non-approved screening tests and what to know.</p>
      </div>
    </div>
    <div class="siteNav" aria-label="Site navigation">
      <a href="index.html" title="Home"><span class="dot" aria-hidden="true"></span>Home</a>
      <a href="breast-pathology-excision-reference.html" title="RadPath">RadPath</a>
      <a href="patient-info.html" class="active" title="Patient information">Patient info</a>
    </div>
  </div>
</header>

<main class="wrap">

<article class="card" id="top">
  <div class="hdr"><div><h2>At a glance</h2><p>Plain-language answers to common questions.</p></div></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why This Information Matters</h2></div></div>
  <div class="body"><p>You may have heard about alternative methods for detecting breast cancer that are marketed as safer, more comfortable, or more effective than mammography. It is important to understand that mammography is the only breast cancer screening method proven to reduce deaths from breast cancer.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup> While some alternative technologies may sound appealing, they have not been shown to be effective for breast cancer screening and are not recommended by major medical organizations.</p><p>This handout explains why certain methods are not approved or recommended for breast cancer screening, so you can make informed decisions about your health.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>For a screening test to be recommended, it must meet several important criteria</h2></div></div>
  <div class="body"><p>• Sensitivity: The ability to correctly identify people who have cancer (avoiding &quot;false negatives&quot; that miss cancers)</p><p>• Specificity: The ability to correctly identify people who do not have cancer (avoiding &quot;false positives&quot; that lead to unnecessary worry and procedures)</p><p>• Proven mortality benefit: Evidence from large, well-designed studies showing that the test actually saves lives by detecting cancer early enough to improve outcomes</p><p>Mammography has been extensively studied and has been shown to reduce breast cancer deaths.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup> The alternative methods described below have not met these standards.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Thermography (Infrared Thermal Imaging)</h2></div></div>
  <div class="body"><p>What it is: Thermography uses infrared cameras to detect heat patterns on the surface of the breast. The theory is that cancerous tissue generates more heat due to increased blood flow and metabolic activity.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why it is not recommended</h2></div></div>
  <div class="body"><p>The National Comprehensive Cancer Network (NCCN) states that &quot;current evidence does not support the use of thermography as a screening procedure.&quot; A systematic review found that thermography has highly variable sensitivity (25% to 97%) and specificity (12% to 85%), meaning it both misses many cancers and produces many false-positive results.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup><sup class="cite"><a href="#ref-2" title="Jump to reference 2">[2]</a></sup></p><p>A classic study published in the New England Journal of Medicine found that thermography had a true-positive rate of only 24% for detecting early-stage breast cancers, meaning it missed about three out of every four cancers.<sup class="cite"><a href="#ref-3" title="Jump to reference 3">[3]</a></sup> More recent studies have confirmed that thermography has low sensitivity (as low as 25%) for detecting breast cancer.<sup class="cite"><a href="#ref-4" title="Jump to reference 4">[4]</a></sup></p><p>The FDA has warned consumers that thermography is not a replacement for mammography and should not be used as a standalone screening tool.<sup class="cite"><a href="#ref-5" title="Jump to reference 5">[5]</a></sup> Despite marketing claims, thermography has never been shown to be effective as a screening method for breast cancer.</p><p>Bottom line: Thermography may miss breast cancers, especially early-stage cancers when treatment is most effective. Using thermography instead of mammography could delay your diagnosis and worsen your outcome.</p></article>

<article class="card">
  <div class="hdr"><div><h2>QT Ultrasound (Quantitative Transmission Ultrasound Tomography)</h2></div></div>
  <div class="body"><p>What it is: QT ultrasound, also called quantitative transmission (QT) imaging or ultrasound tomography, is an emerging technology that uses sound waves to create three-dimensional images of the breast. Unlike standard ultrasound, QT imaging uses a ring of ultrasound transducers to capture images from multiple angles, providing quantitative information about tissue properties such as sound speed and density.<sup class="cite"><a href="#ref-6" title="Jump to reference 6">[6]</a></sup><sup class="cite"><a href="#ref-7" title="Jump to reference 7">[7]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Current status</h2></div></div>
  <div class="body"><p>QT ultrasound is an investigational technology that is still being studied. Early research suggests it may have potential as a breast imaging tool, particularly for younger women who are not yet candidates for mammography.<sup class="cite"><a href="#ref-8" title="Jump to reference 8">[8]</a></sup> In one study comparing QT ultrasound to digital breast tomosynthesis (DBT), QT imaging showed non-inferior performance for detecting breast lesions and had a lower non-cancer recall rate.<sup class="cite"><a href="#ref-8" title="Jump to reference 8">[8]</a></sup><sup class="cite"><a href="#ref-9" title="Jump to reference 9">[9]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why it is not yet recommended for routine screening</h2></div></div>
  <div class="body"><p>• QT ultrasound has not been proven to reduce breast cancer deaths</p><p>• Studies to date have been small and limited<sup class="cite"><a href="#ref-9" title="Jump to reference 9">[9]</a></sup></p><p>• It is not included in any major screening guidelines from organizations such as the NCCN, ACR, or USPSTF</p><p>• It is not widely available and remains primarily a research tool<sup class="cite"><a href="#ref-6" title="Jump to reference 6">[6]</a></sup></p><p>• Long-term outcomes data are lacking</p><p>Bottom line: While QT ultrasound is a promising emerging technology, it has not been validated for routine breast cancer screening. It should not be used as a replacement for mammography until larger studies demonstrate its effectiveness and it receives guideline endorsement.</p></article>

<article class="card">
  <div class="hdr"><div><h2>Automated Whole Breast Ultrasound (ABUS)</h2></div></div>
  <div class="body"><p>Automated Whole Breast Ultrasound (ABUS)</p><p>What it is: Automated breast ultrasound (ABUS) uses a mechanically driven ultrasound transducer to capture standardized, three-dimensional images of the entire breast. Unlike handheld ultrasound, ABUS is less operator-dependent and produces reproducible images that can be compared over time.<sup class="cite"><a href="#ref-10" title="Jump to reference 10">[10]</a></sup><sup class="cite"><a href="#ref-11" title="Jump to reference 11">[11]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Current status</h2></div></div>
  <div class="body"><p>ABUS is FDA-approved as a supplemental screening tool for women with dense breasts who have had a negative mammogram. It is not approved or recommended as a standalone screening method to replace mammography.<sup class="cite"><a href="#ref-10" title="Jump to reference 10">[10]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>What the evidence shows</h2></div></div>
  <div class="body"><p>• ABUS can detect additional mammographically occult cancers in women with dense breasts, with an incremental cancer detection rate of approximately 2-4 per 1,000 women.<sup class="cite"><a href="#ref-12" title="Jump to reference 12">[12]</a></sup><sup class="cite"><a href="#ref-13" title="Jump to reference 13">[13]</a></sup></p><p>• Most cancers detected by ABUS are small, invasive, and node-negative.<sup class="cite"><a href="#ref-12" title="Jump to reference 12">[12]</a></sup></p><p>• However, the BRAID trial found that ABUS detected significantly fewer cancers than abbreviated MRI or contrast-enhanced mammography (4.2 per 1,000 vs. 17.4 per 1,000 for abbreviated MRI).<sup class="cite"><a href="#ref-12" title="Jump to reference 12">[12]</a></sup></p><p>• ABUS increases false-positive findings and recall rates compared to mammography alone.<sup class="cite"><a href="#ref-10" title="Jump to reference 10">[10]</a></sup><sup class="cite"><a href="#ref-11" title="Jump to reference 11">[11]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why it is not recommended as a standalone screening method</h2></div></div>
  <div class="body"><p>• ABUS has not been proven to reduce breast cancer deaths</p><p>• It has a lower cancer detection rate than MRI or contrast-enhanced mammography<sup class="cite"><a href="#ref-12" title="Jump to reference 12">[12]</a></sup></p><p>• It cannot detect calcifications, which are an important sign of some breast cancers<sup class="cite"><a href="#ref-11" title="Jump to reference 11">[11]</a></sup></p><p>• It is intended to be used in addition to mammography, not as a replacement</p><p>Bottom line: ABUS may be offered as a supplemental screening tool for women with dense breasts after a negative mammogram, but it should not replace mammography. If you have dense breasts and are considering supplemental screening, discuss your options with your doctor.</p>
</article>

<article class="card">
  <div class="hdr"><div><h2>Molecular Breast Imaging (MBI) and Breast-Specific Gamma Imaging (BSGI)</h2></div></div>
  <div class="body"><p>What they are: Molecular breast imaging (MBI) and breast-specific gamma imaging (BSGI) are nuclear medicine techniques that use an injected radioactive tracer (technetium-99m sestamibi) to detect metabolically active areas in the breast that may indicate cancer.<sup class="cite"><a href="#ref-14" title="Jump to reference 14">[14]</a></sup><sup class="cite"><a href="#ref-15" title="Jump to reference 15">[15]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Current status</h2></div></div>
  <div class="body"><p>MBI and BSGI are not recommended for routine breast cancer screening in average-risk women.<sup class="cite"><a href="#ref-16" title="Jump to reference 16">[16]</a></sup> However, MBI may be considered as a supplemental screening option for high-risk women who cannot undergo breast MRI.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>What the evidence shows</h2></div></div>
  <div class="body"><p>• MBI can detect additional cancers in women with dense breasts, with an incremental cancer detection rate of approximately 3.5-6.7 per 1,000 women when added to mammography.<sup class="cite"><a href="#ref-17" title="Jump to reference 17">[17]</a></sup><sup class="cite"><a href="#ref-18" title="Jump to reference 18">[18]</a></sup></p><p>• The Density MATTERS trial found that adding MBI to digital breast tomosynthesis increased invasive cancer detection by 2.5-fold.<sup class="cite"><a href="#ref-17" title="Jump to reference 17">[17]</a></sup></p><p>• MBI has similar sensitivity but improved specificity compared to ultrasound.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why it is not recommended for routine screening</h2></div></div>
  <div class="body"><p>• MBI involves radiation exposure that is higher than standard mammography (approximately 4-fold higher whole-body effective dose).<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup><sup class="cite"><a href="#ref-19" title="Jump to reference 19">[19]</a></sup></p><p>• There is insufficient evidence to support its use in average-risk women.<sup class="cite"><a href="#ref-16" title="Jump to reference 16">[16]</a></sup></p><p>• It requires an intravenous injection and takes approximately 40 minutes.<sup class="cite"><a href="#ref-16" title="Jump to reference 16">[16]</a></sup></p><p>• It has not been proven to reduce breast cancer deaths</p><p>Bottom line: MBI may be an option for high-risk women who cannot undergo breast MRI, but it is not recommended for routine screening due to radiation exposure and limited evidence. Discuss with your doctor whether MBI is appropriate for your situation.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Contras-Enhanced Mammography (CEM)</h2></div></div>
  <div class="body"><p>What it is: Contrast-enhanced mammography (CEM) combines standard mammography with an intravenous injection of iodinated contrast material to highlight areas of increased blood flow that may indicate cancer.<sup class="cite"><a href="#ref-20" title="Jump to reference 20">[20]</a></sup><sup class="cite"><a href="#ref-21" title="Jump to reference 21">[21]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Current status</h2></div></div>
  <div class="body"><p>CEM is an emerging supplemental screening tool that shows promise for women at increased risk of breast cancer. It is not yet recommended for routine screening in average-risk women due to limited data.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>What the evidence shows</h2></div></div>
  <div class="body"><p>• CEM has demonstrated superior sensitivity compared to standard mammography (87.5%-90.5% vs. 50.0%-52.4%) and achieved an incremental cancer detection rate of 6.6 to 19.2 per 1,000 in women at elevated risk.<sup class="cite"><a href="#ref-13" title="Jump to reference 13">[13]</a></sup><sup class="cite"><a href="#ref-22" title="Jump to reference 22">[22]</a></sup></p><p>• The BRAID trial found that CEM detected cancers at rates similar to abbreviated MRI (19.2 per 1,000 vs. 17.4 per 1,000).<sup class="cite"><a href="#ref-12" title="Jump to reference 12">[12]</a></sup></p><p>• CEM may be noninferior to breast MRI for cancer detection.<sup class="cite"><a href="#ref-23" title="Jump to reference 23">[23]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why it is not yet recommended for routine screening</h2></div></div>
  <div class="body"><p>• Limited data exist regarding its use for breast cancer screening in average-risk women.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p><p>• It carries a risk of contrast reactions (approximately 0.82% of patients experience a reaction).<sup class="cite"><a href="#ref-13" title="Jump to reference 13">[13]</a></sup></p><p>• It involves a slightly increased radiation dose compared to standard mammography.<sup class="cite"><a href="#ref-21" title="Jump to reference 21">[21]</a></sup></p><p>• It has not been proven to reduce breast cancer deaths</p><p>Current guideline recommendations: NCCN guidelines state that CEM may be considered for high-risk women who cannot undergo MRI.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup> The ACR-sponsored CMIST trial is currently evaluating CEM for screening women with dense breasts.<sup class="cite"><a href="#ref-13" title="Jump to reference 13">[13]</a></sup></p><p>Bottom line: CEM is a promising technology that may become a screening option for women at increased risk, but more research is needed. It is not currently recommended for routine screening in average-risk women.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Breast Self-Examination (BSE)</h2></div></div>
  <div class="body"><p>The U.S. Preventive Services Task Force (USPSTF), American Academy of Family Physicians (AAFP), and American Cancer Society (ACS) recommend against teaching breast self-examination because of a lack of evidence that it improves outcomes and because of potential harms from false-positive findings.<sup class="cite"><a href="#ref-24" title="Jump to reference 24">[24]</a></sup><sup class="cite"><a href="#ref-25" title="Jump to reference 25">[25]</a></sup><sup class="cite"><a href="#ref-26" title="Jump to reference 26">[26]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Two large randomized trials involving over 388,000 women</h2></div></div>
  <div class="body"><p>• Found that breast self-examination does not reduce breast cancer deaths<sup class="cite"><a href="#ref-27" title="Jump to reference 27">[27]</a></sup></p><p>• It almost doubles the number of benign (non-cancerous) biopsies performed, causing unnecessary anxiety, discomfort, and medical costs<sup class="cite"><a href="#ref-27" title="Jump to reference 27">[27]</a></sup></p><p>What is recommended instead: Rather than formal breast self-examination, medical organizations recommend &quot;breast self-awareness&quot;—being familiar with how your breasts normally look and feel and promptly reporting any changes to your healthcare provider.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup><sup class="cite"><a href="#ref-24" title="Jump to reference 24">[24]</a></sup> This is different from a structured monthly self-exam. Approximately 43% to 71% of breast cancers are self-detected by women who notice a change, which supports the value of being aware of your breasts without performing a formal examination.<sup class="cite"><a href="#ref-24" title="Jump to reference 24">[24]</a></sup></p><p>Bottom line: You do not need to perform a formal monthly breast self-examination. Instead, be aware of how your breasts normally look and feel, and tell your doctor if you notice any changes.</p><p>Clinical Breast Examination (CBE)</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why evidence is limited</h2></div></div>
  <div class="body"><p>The USPSTF and AAFP state that there is insufficient evidence to assess the benefits and harms of clinical breast examinations for screening.<sup class="cite"><a href="#ref-25" title="Jump to reference 25">[25]</a></sup><sup class="cite"><a href="#ref-28" title="Jump to reference 28">[28]</a></sup> The American Cancer Society (ACS) recommends against routine clinical breast examinations for average-risk women because of insufficient evidence of benefit and a high rate of false-positive results (55 false-positives for every breast cancer detected).<sup class="cite"><a href="#ref-26" title="Jump to reference 26">[26]</a></sup></p><p>No randomized trials have compared clinical breast examination alone versus no screening to determine if it reduces breast cancer deaths.<sup class="cite"><a href="#ref-28" title="Jump to reference 28">[28]</a></sup></p><p>What is recommended: While clinical breast examination is not recommended as a standalone screening method, some organizations (including NCCN and ACOG) still recommend it as part of a clinical encounter, particularly for ongoing risk assessment and counseling.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup> If you have a breast concern or symptom, a clinical breast examination is an important part of your evaluation.</p><p>Bottom line: Clinical breast examination alone has not been proven to save lives when used for screening. However, it may still be performed as part of your regular healthcare visits for risk assessment and to evaluate any symptoms you may have.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Electrical Impedance Scanning (EIS)</h2></div></div>
  <div class="body"><p>What it is: Electrical impedance scanning measures the electrical properties of breast tissue. The theory is that cancer cells have different electrical conductivity than normal cells.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Why it is not recommended</h2></div></div>
  <div class="body"><p>Systematic reviews have found insufficient evidence to recommend electrical impedance scanning for breast cancer screening.<sup class="cite"><a href="#ref-2" title="Jump to reference 2">[2]</a></sup> Studies have shown:</p><p>• Highly variable sensitivity (26% to 98%) and specificity (8% to 81%)<sup class="cite"><a href="#ref-2" title="Jump to reference 2">[2]</a></sup></p><p>• Significant heterogeneity among studies, making it difficult to draw reliable conclusions<sup class="cite"><a href="#ref-2" title="Jump to reference 2">[2]</a></sup></p><p>• High false-positive rates that lead to unnecessary biopsies and anxiety</p><p>• No studies demonstrating that it reduces breast cancer deaths<sup class="cite"><a href="#ref-2" title="Jump to reference 2">[2]</a></sup></p><p>Bottom line: Electrical impedance scanning has not been proven effective for breast cancer screening and is not recommended by medical organizations.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>Blood Tests and Biomarkers</h2></div></div>
  <div class="body"><p>Currently, no blood test is approved or recommended for breast cancer screening in average-risk women. While tumor markers such as CA 15-3 and CEA are used in some situations (such as monitoring treatment response in patients with advanced breast cancer), they are not sensitive enough to detect early breast cancer.</p><p>Research is ongoing to develop blood-based tests for early cancer detection, including &quot;multi-cancer early detection&quot; (MCED) tests. However, these tests:</p><p>• Are still in early stages of development and clinical validation</p><p>• Have not been proven to reduce breast cancer deaths</p><p>• Are not currently recommended as a replacement for mammography</p><p>Bottom line: There is no blood test that can replace mammography for breast cancer screening. If you see advertisements for blood tests claiming to detect breast cancer early, be aware that these are not proven or recommended screening methods.</p><p>Other Emerging or Unproven Methods</p><p>Several other technologies have been promoted for breast cancer screening but lack sufficient evidence:</p><p>• Optical imaging: Uses light to image breast tissue. Not supported by sufficient evidence for screening.</p><p>• Elastography: Measures tissue stiffness using ultrasound. While useful as an adjunct to ultrasound for evaluating known breast lesions, it is not recommended for screening.<sup class="cite"><a href="#ref-2" title="Jump to reference 2">[2]</a></sup></p><p>• Positron emission mammography (PEM): A nuclear medicine technique similar to PET scanning. Not recommended for routine screening due to radiation exposure and limited evidence.</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>What IS Recommended for Breast Cancer Screening?</h2></div></div>
  <div class="body"><p>The following methods are supported by evidence and recommended by major medical organizations:</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>For average-risk women</h2></div></div>
  <div class="body"><p>• Mammography (preferably with tomosynthesis/3D mammography) is the foundation of breast cancer screening and is the only method proven to reduce breast cancer deaths.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>For women at increased risk</h2></div></div>
  <div class="body"><p>• Mammography plus breast MRI is recommended for women at high risk (≥20% lifetime risk), including those with BRCA mutations or a strong family history.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p><p>• Supplemental screening with contrast-enhanced mammography (CEM) or molecular breast imaging (MBI) may be considered for high-risk women who cannot undergo MRI.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p><p>• Whole breast ultrasound may be done if contrast-enhanced imaging or functional imaging is not available.<sup class="cite"><a href="#ref-1" title="Jump to reference 1">[1]</a></sup></p><p>Understanding the Difference: Approved Supplemental Screening vs. Unproven Alternatives</p></div>
</article>

<article class="card">
  <div class="hdr"><div><h2>It is important to understand the difference between</h2></div></div>
  <div class="body"><p>Approved supplemental screening methods (used IN ADDITION to mammography for specific populations):</p></div>
</article>


<article class="card" id="references">
  <div class="hdr"><div><h2>References</h2><p>Citations in the text link here.</p></div></div>
  <div class="body">
    <details class="refsDetails">
      <summary>
        <div class="sleft"><b>Show references</b><span>Click to expand/collapse the bibliography</span></div>
        <span class="badge">Toggle</span>
      </summary>
      <div class="detailbody"><div class="refs">
  <div class="ref" id="ref-1">
    <div class="rid">[1] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Breast Cancer Screening and Diagnosis. National Comprehensive Cancer Network. Updated 2025-03-28.</div>
  </div>

  <div class="ref" id="ref-2">
    <div class="rid">[2] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">A Systematic Review of Elastography, Electrical Impedance Scanning, and Digital Infrared Thermography for Breast Cancer Screening and Diagnosis. Vreugdenburg TD, Willis CD, Mundy L, Hiller JE. Breast Cancer Research and Treatment. 2013;137(3):665-76. doi:10.1007/s10549-012-2393-x.</div>
  </div>

  <div class="ref" id="ref-3">
    <div class="rid">[3] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Lack of Efficacy of Thermography as a Screening Tool for Minimal and Stage I Breast Cancer. Moskowitz M, Milbrath J, Gartside P, Zermeno A, Mandel D. The New England Journal of Medicine. 1976;295(5):249-52. doi:10.1056/NEJM197607292950504.</div>
  </div>

  <div class="ref" id="ref-4">
    <div class="rid">[4] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Digital Infrared Thermal Imaging (DITI) of Breast Lesions: Sensitivity and Specificity of Detection of Primary Breast Cancers. Kontos M, Wilson R, Fentiman I. Clinical Radiology. 2011;66(6):536-9. doi:10.1016/j.crad.2011.01.009.</div>
  </div>

  <div class="ref" id="ref-5">
    <div class="rid">[5] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Risks of Online Advertisement of Direct-to-Consumer Thermography for Breast Cancer Screening. Lovett KM, Liang BA. Nature Reviews. Cancer. 2011;11(12):827-8. doi:10.1038/nrc3170.</div>
  </div>

  <div class="ref" id="ref-6">
    <div class="rid">[6] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Ultrasound Tomography. Ruiter NV, Zapf M, Hopp T, Gemmeke H. Advances in Experimental Medicine and Biology. 2023;1403:171-200. doi:10.1007/978-3-031-21987-0_9.</div>
  </div>

  <div class="ref" id="ref-7">
    <div class="rid">[7] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Objective Breast Tissue Image Classification Using Quantitative Transmission Ultrasound Tomography. Malik B, Klock J, Wiskin J, Lenox M. Scientific Reports. 2016;6:38857. doi:10.1038/srep38857.</div>
  </div>

  <div class="ref" id="ref-8">
    <div class="rid">[8] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">A Multireader Multicase (MRMC) Receiver Operating Characteristic (ROC) Study Evaluating Noninferiority of Quantitative Transmission (QT) Ultrasound to Digital Breast Tomosynthesis (DBT) on Detection and Recall of Breast Lesions. Jiang Y, Iuanow E, Malik B, Klock J. Academic Radiology. 2024;31(6):2248-2258. doi:10.1016/j.acra.2023.12.038.</div>
  </div>

  <div class="ref" id="ref-9">
    <div class="rid">[9] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">An Exploratory Multi-Reader, Multi-Case Study Comparing Transmission Ultrasound to Mammography on Recall Rates and Detection Rates for Breast Cancer Lesions. Malik B, Iuanow E, Klock J. Academic Radiology. 2022;29 Suppl 1:S10-S18. doi:10.1016/j.acra.2020.11.011.</div>
  </div>

  <div class="ref" id="ref-10">
    <div class="rid">[10] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Pearls and Pitfalls of Interpretation of Automated Breast US. Huppe AI, Inciardi MF, Aripoli AM, et al. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2023;43(10):e230023. doi:10.1148/rg.230023.</div>
  </div>

  <div class="ref" id="ref-11">
    <div class="rid">[11] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Automated Three-Dimensional Breast US for Screening: Technique, Artifacts, and Lesion Characterization. van Zelst JCM, Mann RM. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2018 May-Jun;38(3):663-683. doi:10.1148/rg.2018170162.</div>
  </div>

  <div class="ref" id="ref-12">
    <div class="rid">[12] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Comparison of Supplemental Breast Cancer Imaging Techniques-Interim Results From the BRAID Randomised Controlled Trial. Gilbert FJ, Payne NR, Allajbeu I, et al. Lancet (London, England). 2025;405(10493):1935-1944. doi:10.1016/S0140-6736(25)00582-3.</div>
  </div>

  <div class="ref" id="ref-13">
    <div class="rid">[13] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Breast Cancer Screening for Women at Higher-Than-Average Risk: Updated Recommendations From the ACR. Monticciolo DL, Newell MS, Moy L, Lee CS, Destounis SV. Journal of the American College of Radiology : JACR. 2023;20(9):902-914. doi:10.1016/j.jacr.2023.04.002.</div>
  </div>

  <div class="ref" id="ref-14">
    <div class="rid">[14] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Molecular Breast Imaging in Clinical Practice. Dibble EH, Hunt KN, Ehman EC, O&#x27;Connor MK. AJR. American Journal of Roentgenology. 2020;215(2):277-284. doi:10.2214/AJR.19.22622.</div>
  </div>

  <div class="ref" id="ref-15">
    <div class="rid">[15] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Advances and Future Directions in Molecular Breast Imaging. Covington MF, Parent EE, Dibble EH, Rauch GM, Fowler AM. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 2022;63(1):17-21. doi:10.2967/jnumed.121.261988.</div>
  </div>

  <div class="ref" id="ref-16">
    <div class="rid">[16] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">ACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density: 2024 Update. Expert Panel on Breast Imaging, Paulis LV, Lewin AA, et al. Journal of the American College of Radiology : JACR. 2025;22(5S):S405-S423. doi:10.1016/j.jacr.2025.02.023.</div>
  </div>

  <div class="ref" id="ref-17">
    <div class="rid">[17] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial. Hruska CB, Hunt KN, Larson NB, et al. Radiology. 2025;316(3):e243953. doi:10.1148/radiol.243953.</div>
  </div>

  <div class="ref" id="ref-18">
    <div class="rid">[18] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Supplemental Breast Cancer Screening With Molecular Breast Imaging for Women With Dense Breast Tissue. Shermis RB, Wilson KD, Doyle MT, et al. AJR. American Journal of Roentgenology. 2016;207(2):450-7. doi:10.2214/AJR.15.15924.</div>
  </div>

  <div class="ref" id="ref-19">
    <div class="rid">[19] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Screening Algorithms in Dense Breasts: AJR Expert Panel Narrative Review. Berg WA, Rafferty EA, Friedewald SM, Hruska CB, Rahbar H. AJR. American Journal of Roentgenology. 2021;216(2):275-294. doi:10.2214/AJR.20.24436.</div>
  </div>

  <div class="ref" id="ref-20">
    <div class="rid">[20] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Contrast-Enhanced Mammography: State of the Art. Jochelson MS, Lobbes MBI. Radiology. 2021;299(1):36-48. doi:10.1148/radiol.2021201948.</div>
  </div>

  <div class="ref" id="ref-21">
    <div class="rid">[21] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Contrast-Enhanced Mammography in Breast Cancer Screening. Coffey K, Jochelson MS. European Journal of Radiology. 2022;156:110513. doi:10.1016/j.ejrad.2022.110513.</div>
  </div>

  <div class="ref" id="ref-22">
    <div class="rid">[22] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Screening for Breast Cancer With Contrast-Enhanced Mammography as an Alternative to MRI: SCEMAM Trial Results. Berg WA, Vargo A, Lu AH, et al. Radiology. 2025;315(3):e242634. doi:10.1148/radiol.242634.</div>
  </div>

  <div class="ref" id="ref-23">
    <div class="rid">[23] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Comparison of Contrast-Enhanced Mammography With MRI Utilizing an Enriched Reader Study: A Breast Cancer Study (CONTRRAST Trial). Phillips J, Mehta TS, Portnow LH, et al. Radiology. 2023;309(2):e230530. doi:10.1148/radiol.230530.</div>
  </div>

  <div class="ref" id="ref-24">
    <div class="rid">[24] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Practice Bulletin Number 179: Breast Cancer Risk Assessment and Screening in Average-Risk Women. Obstetrics and Gynecology. 2017;130(1):e1-e16. doi:10.1097/AOG.0000000000002158.</div>
  </div>

  <div class="ref" id="ref-25">
    <div class="rid">[25] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Breast Cancer Screening: Common Questions and Answers. Khan M, Chollet A. American Family Physician. 2021;103(1):33-41.</div>
  </div>

  <div class="ref" id="ref-26">
    <div class="rid">[26] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. Oeffinger KC, Fontham ET, Etzioni R, et al. JAMA. 2015;314(15):1599-614. doi:10.1001/jama.2015.12783.</div>
  </div>

  <div class="ref" id="ref-27">
    <div class="rid">[27] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Regular Self-Examination or Clinical Examination for Early Detection of Breast Cancer. Kösters JP, Gøtzsche PC. The Cochrane Database of Systematic Reviews. 2003;(2):CD003373. doi:10.1002/14651858.CD003373.</div>
  </div>

  <div class="ref" id="ref-28">
    <div class="rid">[28] <a href="#top" title="Back to top">↑</a></div>
    <div class="rbody">Screening for Breast Cancer in Average-Risk Women: A Guidance Statement From the American College of Physicians. Qaseem A, Lin JS, Mustafa RA, et al. Annals of Internal Medicine. 2019;170(8):547-560. doi:10.7326/M18-2147.</div>
  </div></div></div>
    </details>
  </div>
</article>

</main>

<script>
function openRefsIfNeeded(){
  const h=(location.hash||"").toLowerCase();
  const d=document.querySelector(".refsDetails");
  if(!d) return;
  if(h==="#references" || h.startsWith("#ref-")) d.open=true;
}
window.addEventListener("hashchange", openRefsIfNeeded);
document.addEventListener("click",(e)=>{
  const a=e.target && e.target.closest ? e.target.closest('a[href^="#ref-"], a[href="#references"]') : null;
  if(!a) return;
  const d=document.querySelector(".refsDetails");
  if(d) d.open=true;
});
openRefsIfNeeded();
</script>

</body>
</html>
